Kamada Shares Rise 16% on Earnings Outlook, Trial Progress

Dow Jones

Jan 09, 2025

By Katherine Hamilton

Kamada shares climbed after the company released its guidance for 2025 and updated its progress on a therapy trial.

The biopharmaceutical company's stock advanced 16% to $7.92. Shares have gained 30% over the past 12 months.

Kamada expects to earn $178 million to $182 million in revenue during 2025, which would be a 13% increase from the previous year. It anticipates $38 million to $42 million in adjusted EBITDA.

The company affirmed guidance for $158 million to $162 million in annual revenue in 2024. Year-end cash should be around $78 million, it said. Adjusted EBITDA is anticipated to be $32 million to $35 million.

The operational cash will provide resources for new business development and mergers and acquisitions in 2025, Chief Executive Amir London said. Kamada also plans to expand its plasma collection operations, including opening a third location in San Antonio in the first quarter of 2025.

Kamada expects to advance its phase-three trial of its Inhaled Alpha-1 Antitrypsin therapy. The FDA confirmed an agreement for the trial, which will allow Kamada to reduce the study sample size from 220 patients to 180 while maintaining statistical power. An interim futility analysis is expected to happen by the end of 2025.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

January 08, 2025 14:06 ET (19:06 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2502701058"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2502701058\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2502701058?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-09 03:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2502701058","market":"sg","top_or_hot":-1,"title":"Kamada Shares Rise 16% on Earnings Outlook, Trial Progress","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<p>\n  Kamada shares climbed after the company released its guidance for 2025 and updated its progress on a therapy trial. \n</p>\n<p>\n  The biopharmaceutical company's stock advanced 16% to $7.92. Shares have gained 30% over the past 12 months. \n</p>\n<p>\n  Kamada expects to earn $178 million to $182 million in revenue during 2025, which would be a 13% increase from the previous year. It anticipates $38 million to $42 million in adjusted EBITDA. \n</p>\n<p>\n  The company affirmed guidance for $158 million to $162 million in annual revenue in 2024. Year-end cash should be around $78 million, it said. Adjusted EBITDA is anticipated to be $32 million to $35 million. \n</p>\n<p>\n  The operational cash will provide resources for new business development and mergers and acquisitions in 2025, Chief Executive Amir London said. Kamada also plans to expand its plasma collection operations, including opening a third location in San Antonio in the first quarter of 2025. \n</p>\n<p>\n  Kamada expects to advance its phase-three trial of its Inhaled Alpha-1 Antitrypsin therapy. The FDA confirmed an agreement for the trial, which will allow Kamada to reduce the study sample size from 220 patients to 180 while maintaining statistical power. An interim futility analysis is expected to happen by the end of 2025. \n</p>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 08, 2025 14:06 ET (19:06 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kamada Shares Rise 16% on Earnings Outlook, Trial Progress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKamada Shares Rise 16% on Earnings Outlook, Trial Progress\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-01-09 03:06</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<p>\n  Kamada shares climbed after the company released its guidance for 2025 and updated its progress on a therapy trial. \n</p>\n<p>\n  The biopharmaceutical company's stock advanced 16% to $7.92. Shares have gained 30% over the past 12 months. \n</p>\n<p>\n  Kamada expects to earn $178 million to $182 million in revenue during 2025, which would be a 13% increase from the previous year. It anticipates $38 million to $42 million in adjusted EBITDA. \n</p>\n<p>\n  The company affirmed guidance for $158 million to $162 million in annual revenue in 2024. Year-end cash should be around $78 million, it said. Adjusted EBITDA is anticipated to be $32 million to $35 million. \n</p>\n<p>\n  The operational cash will provide resources for new business development and mergers and acquisitions in 2025, Chief Executive Amir London said. Kamada also plans to expand its plasma collection operations, including opening a third location in San Antonio in the first quarter of 2025. \n</p>\n<p>\n  Kamada expects to advance its phase-three trial of its Inhaled Alpha-1 Antitrypsin therapy. The FDA confirmed an agreement for the trial, which will allow Kamada to reduce the study sample size from 220 patients to 180 while maintaining statistical power. An interim futility analysis is expected to happen by the end of 2025. \n</p>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 08, 2025 14:06 ET (19:06 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PRGS","symbol_name":"Progress Software Corporation","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2502701058","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2502701058","pubTimestamp":1736363160,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Kamada shares climbed after the company released its guidance for 2025 and updated its progress on a therapy trial.The biopharmaceutical company's stock advanced 16% to $7.92. Shares have gained 30% over the past 12 months.Kamada expects to earn $178 million to $182 million in revenue during 2025, which would be a 13% increase from the previous year. It anticipates $38 million to $42 million in adjusted EBITDA.The company affirmed guidance for $158 million to $162 million in annual revenue in 2024. Year-end cash should be around $78 million, it said. Adjusted EBITDA is anticipated to be $32 million to $35 million.Kamada expects to advance its phase-three trial of its Inhaled Alpha-1 Antitrypsin therapy. The FDA confirmed an agreement for the trial, which will allow Kamada to reduce the study sample size from 220 patients to 180 while maintaining statistical power. An interim futility analysis is expected to happen by the end of 2025.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"PRGS":"Progress Software Corporation","KMDA":"Kamada Ltd."},"translate_title":"Kamada股价因盈利前景和试验进展而上涨16%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KMDA":1,"PRGS":1},"content_text":"By Katherine Hamilton \n\n\n  Kamada shares climbed after the company released its guidance for 2025 and updated its progress on a therapy trial. \n\n\n  The biopharmaceutical company's stock advanced 16% to $7.92. Shares have gained 30% over the past 12 months. \n\n\n  Kamada expects to earn $178 million to $182 million in revenue during 2025, which would be a 13% increase from the previous year. It anticipates $38 million to $42 million in adjusted EBITDA. \n\n\n  The company affirmed guidance for $158 million to $162 million in annual revenue in 2024. Year-end cash should be around $78 million, it said. Adjusted EBITDA is anticipated to be $32 million to $35 million. \n\n\n  The operational cash will provide resources for new business development and mergers and acquisitions in 2025, Chief Executive Amir London said. Kamada also plans to expand its plasma collection operations, including opening a third location in San Antonio in the first quarter of 2025. \n\n\n  Kamada expects to advance its phase-three trial of its Inhaled Alpha-1 Antitrypsin therapy. The FDA confirmed an agreement for the trial, which will allow Kamada to reduce the study sample size from 220 patients to 180 while maintaining statistical power. An interim futility analysis is expected to happen by the end of 2025. \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n  (END) Dow Jones Newswires\n\n\n  January 08, 2025 14:06 ET (19:06 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}